Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial.

Antonarakis, Emmanuel S; Armstrong, Andrew J; Morris, Michael J; Beltran, Himisha; Halabi, Susan; Gaughan, Luke; Li, Yingming; Dehm, Scott M; Knutson, Todd P; Luo, Bin; Guo, Siyuan; Ryan, Charles J; Heer, Rakesh; Yu, Chenxi; Valentín López, José C; Kobilka, Anna; Lyman, Jacqueline; Munro, Sarah A

doi:10.1158/1078-0432.CCR-25-2779

Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial.

2026-06-15, Clinical Cancer Research (10.1158/1078-0432.CCR-25-2779) (online)
Emmanuel S Antonarakis, Andrew J Armstrong, Michael J Morris, Himisha Beltran, Susan Halabi, Luke Gaughan, Yingming Li, Scott M Dehm, Todd P Knutson, Bin Luo, Siyuan Guo, Charles J Ryan, Rakesh Heer, Chenxi Yu, José C Valentín López, Anna Kobilka, Jacqueline Lyman, and Sarah A Munro (?)

Androgen receptor pathway inhibitors (ARPI), such as enzalutamide and abiraterone, are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, a subset of patients display primary resistance and most eventually acquire secondary resistance. This study aimed to define genomic features of ARPI resistance using longitudinal ctDNA analysis.

This article has not yet been included in any curations.

Comments

There are no comments on this article yet.

You need to login or register to comment.

BioSothis

Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial.